Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:

NCT ID: NCT03580343 Active, not recruiting - Uveitis Clinical Trials

Tofacitinib for Inflammatory Eye Disease

Start date: April 4, 2019
Phase: Phase 2
Study type: Interventional

Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic, auto-immune process that leads to vision loss. While steroids are effective in the short term, the side-effect profile of chronic steroid use necessitates the identification of effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.

NCT ID: NCT03467490 Active, not recruiting - Dry Eye Disease Clinical Trials

Self-care Management Program for Dry Eye Disease Patients Using the heiQ

heiQ
Start date: November 24, 2018
Phase: N/A
Study type: Interventional

Dry Eye Disease (DED)is a chronic disease without a cure. Empowering patients to engage in better self-care requires knowledge of their disease and skills in self-management, which can lead to improved well-being and quality of life. The Investigation team has developed a DED self-management program (video series and educational booklet) that can be easily implemented into clinical use. The Investigators are going to use the Ocular Surface Disease Index (OSDI) to measure the dry eye in the participants. In addition, the research team plans to use the heiQ (validated questionnaire that assesses self-management and health education programs) to evaluate the DED self-management program by comparing results taken at baseline to 2 months after undergoing the self-management program.

NCT ID: NCT03122847 Active, not recruiting - Clinical trials for Graves Ophthalmopathy

Glucocorticoids and Bone in Graves' Ophthalmopathy

Start date: June 7, 2017
Phase:
Study type: Observational

Continuous use of systemic glucocorticoids decreases bone mineral density and increases fracture risk. Graves' orbitopathy is treated with weekly infusion of high-dose intravenous glucocorticoid. The investigators aim at investigating whether this treatment regimen also affects bone metabolism.

NCT ID: NCT02405039 Active, not recruiting - Dry Eye Clinical Trials

Study of EBI-005 in Dry Eye Disease (DED)

EBI-005
Start date: April 2015
Phase: Phase 3
Study type: Interventional

This is a randomized, double masked study designed to evaluate the safety of EBI-005 5 mg/mL topical ophthalmic solution given three times daily (TID) compared to vehicle-control over a one year period in subjects with dry eye disease (DED). Approximately 188 subjects will be enrolled to either EBI-005 or vehicle at up to 15 centers in the United States (US) and Canada.

NCT ID: NCT02378298 Active, not recruiting - Clinical trials for Ophthalmopathy, Thyroid-Associated

Rituximab (RTX) Therapy in Patients With Active TAO

Start date: December 2011
Phase: Phase 4
Study type: Interventional

Thyroid Associated Ophthalmopathy is condition affecting the eyes of about 10% of patients with Graves disease. Its combination of protrusion affecting the looks of the patient and pain is often severely affecting the quality of life among these patients. The standard treatment for this illness today is intravenous glucocorticoids together with methotrexate. The purpose of this study is to evaluate the effect of rituximab on patients that do not respond to or relapse after conventional therapy.

NCT ID: NCT01880463 Active, not recruiting - Dry Eye Disease Clinical Trials

Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)

Start date: July 2010
Phase: N/A
Study type: Interventional

The VITamin D and OmegA-3 Trial (VITAL; NCT 01169259) is a randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether omega-3 fatty acids or vitamin D3, compared to placebo, reduce the incidence and/or progression of dry eye disease.

NCT ID: NCT01763411 Active, not recruiting - Cataract Clinical Trials

Visual Performance of Pseudophakic Patient With Different Intraocular Lenses

ETDRS
Start date: January 2008
Phase: N/A
Study type: Observational

This retrospective study comprised patients with cataract, corneal astigmatism, and motivation for spectacle independence. In all cases, a multifocal and monofocal Intraocular Lens was been implanted in the capsular bag. Three months postoperatively, distance, intermediate, and near visual acuities; spherical equivalent; residual refractive astigmatism; defocus curve; and contrast sensitivity was evaluated. A patient-satisfaction and visual phenomena questionnaire was also been administered.

NCT ID: NCT01648452 Active, not recruiting - Eye Disease Clinical Trials

CNTF Implants for CNGB3 Achromatopsia

CNTF-CNGB3-1
Start date: July 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Background: - Achromatopsia is an inherited condition that causes vision loss because cells in the retina do not work properly. It causes loss of acuity, sensitivity to light, and loss of color vision. There are no effective treatments for achromatopsia. - Four genes currently are known to cause achromatopsia. One of these, the cyclic nucleotide-gated channel beta 3 (CNGB3) gene, is the cause in about 50 percent of people. - CNTF is a natural chemical found in the body that promotes survival and function of nerve cells. CNTF has been shown to be effective in treating retinal disease in animals and can slow vision loss. - CNTF has also been studied in over 250 people with retinal disease other than achromatopsia. In these studies, a CNTF implant was placed into the eye during a simple surgery. The implant releases CNTF inside the eye, near the retina. These studies suggested that a CNTF implant might help vision in some eye diseases. Objectives: - To learn whether a CNTF implant is safe for people with CNGB3 achromatopsia. - To learn whether CNTF can improve visual acuity or color vision, and whether it may reduce sensitivity to light in people with CNGB3 achromatopsia. Eligibility: You may be able to take part in this study if you: - Are at least 18 years old. - Test positive for mutations in the CNGB3 gene and have no mutations in another achromatopsia gene. - Have 20/100 vision or worse in at least one eye. - Are not pregnant or nursing. Design: - To determine if you can take part, we will ask about your medical history and do a physical examination and an eye examination. Blood and urine samples will be taken. - This study requires 11 visits to the National Eye Institute over 3 years. - One visit will be for the implant surgery. The implant will be placed in one eye only. - Study visits will take place 1 day after implant surgery, and again 1 week later and 1 month, 3 months, 6 months, 1 year, 1.5 years and 3 years later. These visits will help us evaluate the safety and benefit of the implant on your eye. - At the 3 year visit, you can choose to keep the CNTF implant in your eye, or you can have us remove it.

NCT ID: NCT01217762 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and clinical feasibility of the IRay System for the treatment of wet age-related macular degeneration (AMD).

NCT ID: NCT00594672 Active, not recruiting - Cataract Clinical Trials

Age-Related Eye Disease Study (AREDS) Follow-Up

Start date: June 2, 2008
Phase:
Study type: Observational

This study is a 5-year extension of the AREDS protocol, in which investigators followed the natural course of age-related macular degeneration (AMD) and cataracts. Participants in the former AREDS protocol are eligible for this study. Participants have a complete eye examination once a year and are contacted at least once a year between visits to check on their status. The eye examination includes measurement of visual acuity (vision chart test) and examination of the inside of the eye after the pupils have been dilated with eye drops. Photographs of the inside of the eye may be taken using a special camera that flashes a bright light in the eye. A blood sample may be obtained to test for cholesterol level and genes related to inflammation....